Point missense mutations of NFE2L2 gene were also reported to have a similar effect on the KEAP1/NRF2 binding affinity and frequently recurred not only in lung cancer [40], but also in head and neck carcinoma [41], hepatocellular carcinoma (HCC) [42], papillary renal cell carcinoma (PRCC) [43] as well as esophageal and skin cancers [44]. Here, NFE2L2 is linked to lung carcinoma.